2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

被引:122
|
作者
Aletaha, Daniel [2 ]
Neogi, Tuhina [3 ]
Silman, Alan J. [1 ]
Funovits, Julia [2 ]
Felson, David T. [3 ]
Bingham, Clifton O., III [4 ]
Birnbaum, Neal S. [5 ,6 ]
Burmester, Gerd R. [7 ,8 ]
Bykerk, Vivian P. [9 ,10 ]
Cohen, Marc D. [11 ]
Combe, Bernard [12 ,13 ]
Costenbader, Karen H. [14 ,15 ]
Dougados, Maxime [16 ,17 ]
Emery, Paul [18 ,19 ]
Ferraccioli, Gianfranco [20 ]
Hazes, Johanna M. W. [21 ,22 ]
Hobbs, Kathryn [23 ]
Huizinga, Tom W. J. [24 ]
Kavanaugh, Arthur [25 ]
Kay, Jonathan [26 ,27 ]
Kvien, Tore K. [28 ]
Laing, Timothy [29 ]
Mease, Philip [30 ,31 ]
Menard, Henri A. [32 ]
Moreland, Larry W. [33 ]
Naden, Raymond L. [34 ]
Pincus, Theodore [35 ]
Smolen, Josef S. [2 ]
Stanislawska-Biernat, Ewa [36 ]
Symmons, Deborah [37 ]
Tak, Paul P. [38 ]
Upchurch, Katherine S. [27 ]
Vencovsky, Jiri [39 ]
Wolfe, Frederick [40 ,41 ]
Hawker, Gillian [10 ,42 ]
机构
[1] Arthrit Res UK, Chesterfield S41 7TD, England
[2] Med Univ Vienna, Vienna, Austria
[3] Boston Univ, Sch Med, Boston, MA 02118 USA
[4] Johns Hopkins Univ, Baltimore, MD USA
[5] Univ Calif San Francisco, San Francisco, CA 94143 USA
[6] Calif Pacific Med Ctr, San Francisco, CA USA
[7] Free Univ Berlin, Univ Med Berlin, Charite Hosp, D-1000 Berlin, Germany
[8] Humboldt Univ, Berlin, Germany
[9] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[10] Univ Toronto, Toronto, ON, Canada
[11] Natl Jewish Med & Res Ctr, Denver, CO USA
[12] Lapeyronie Hosp, Montpellier, France
[13] Univ Montpellier I, Montpellier, France
[14] Brigham & Womens Hosp, Boston, MA 02115 USA
[15] Harvard Univ, Boston, MA 02115 USA
[16] Cochin Hosp, AP HP, Paris, France
[17] Paris Descartes Univ, Paris, France
[18] Univ Leeds, Leeds LS2 9JT, W Yorkshire, England
[19] NIHR Leeds Muscoskeletal Biomed Res Unit Leeds, Leeds, W Yorkshire, England
[20] Univ Cattolica Sacro Cuore, Sch Med, I-00168 Rome, Italy
[21] Univ Med Ctr Rotterdam, Erasmus Med Ctr, Rotterdam, Netherlands
[22] Univ Rotterdam, Rotterdam, Netherlands
[23] Univ Colorado, Sch Med, Denver, CO USA
[24] Leiden Univ Med Ctr, Leiden, Netherlands
[25] Univ Calif San Diego, San Diego, CA 92103 USA
[26] UMass Mem Med Ctr, Worcester, MA USA
[27] Univ Massachusetts, Sch Med, Worcester, MA USA
[28] Diakonhjemmet Hosp, Oslo, Norway
[29] Univ Michigan, Ann Arbor, MI 48109 USA
[30] Swedish Med Ctr, Seattle, WA USA
[31] Univ Washington, Seattle, WA 98195 USA
[32] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
[33] Univ Pittsburgh, Pittsburgh, PA USA
[34] Minist Hlth, Auckland, New Zealand
[35] New York Univ Hosp Joint Dis, New York, NY USA
[36] Inst Rheumatol, Warsaw, Poland
[37] Univ Manchester, Manchester, Lancs, England
[38] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[39] Inst Rheumatol, Prague, Czech Republic
[40] Natl Data Bank Rheumat Dis, Wichita, KS USA
[41] Univ Kansas, Wichita, KS USA
[42] Womens Coll Hosp, Toronto, ON M5S 1B2, Canada
关键词
UNDIFFERENTIATED ARTHRITIS; CITRULLINATED PEPTIDE; CONTROLLED-TRIAL; METHOTREXATE; DISEASE; PROGRESSION; ANTIBODIES; THERAPIES; EROSIONS;
D O I
10.1136/ard.2010.138461
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective The 1987 American College of Rheumatology (ACR; formerly the American Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticised for their lack of sensitivity in early disease. This work was undertaken to develop new classification criteria for RA. Methods A joint working group from the ACR and the European League Against Rheumatism developed, in three phases, a new approach to classifying RA. The work focused on identifying, among patients newly presenting with undifferentiated inflammatory synovitis, factors that best discriminated between those who were and those who were not at high risk for persistent and/or erosive disease-this being the appropriate current paradigm underlying the disease construct 'RA'. Results In the new criteria set, classification as 'definite RA' is based on the confirmed presence of synovitis in at least one joint, absence of an alternative diagnosis better explaining the synovitis, and achievement of a total score of 6 or greater (of a possible 10) from the individual scores in four domains: number and site of involved joints (range 0-5), serological abnormality (range 0-3), elevated acute-phase response (range 0-1) and symptom duration (two levels; range 0-1). Conclusion This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features. This will refocus attention on the important need for earlier diagnosis and institution of effective disease-suppressing therapy to prevent or minimise the occurrence of the undesirable sequelae that currently comprise the paradigm underlying the disease construct 'RA'.
引用
收藏
页码:1580 / 1588
页数:9
相关论文
共 50 条